BridgeMD
New treatment option for Adolescent Asthma
Official title Study of RSS0343 Tablets in Patients With Non-cystic Fibrosis Bronchiectasis
ClinicalTrials.gov ID: NCT06775340
What this study is testing
What is RSS0343 Tabella?
RSS0343 Tabella is an investigational medicine, given as a pill taken by mouth, being studied as a potential treatment for adolescent asthma.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- Studies to evaluate the safety, tolerability, pharmacodynamics, and efficacy of RSS0343 tablets in patients with non-cystic fibrosis bronchiectasis
- Phase 2: a mid-size study of how well it works
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 75
You may be able to join if
- Age 18-75 years old (including boundary values), male and female.
- Female people weigh ≥45 kg and male people weigh ≥50 kg.
- HRCT shows bronchiectasis affecting one or more lobes of the lung and is confirmed by the clinician as NCFB.
- The expected survival is greater than 12 months.
- Informed consent was signed before the trial.
You likely can't join if
- Patients with pulmonary hypertension or chronic obstructive pulmonary disease (COPD) or asthma as determined by the investigators were the primary...
- An active, symptomatic infection caused by respiratory viruses, including COVID-19, influenza viruses, etc.
- Have psoriasis or lichen planus.
- Have Wright's disease/keratosis or hemorrhagic keratosis, or reactive arthritis.
- Have chlorine acne, large common warts, or keratodermatitis.
- Has diabetic foot.
See the full eligibility criteria
- Age 18-75 years old (including boundary values), male and female.
- Female people weigh ≥45 kg and male people weigh ≥50 kg.
- HRCT shows bronchiectasis affecting one or more lobes of the lung and is confirmed by the clinician as NCFB.
- The expected survival is greater than 12 months.
- Informed consent was signed before the trial.
- Potentially fertile people voluntarily take appropriate contraceptive measures.
- Patients with pulmonary hypertension or chronic obstructive pulmonary disease (COPD) or asthma as determined by the investigators were the primary diagnosis were screened.
- An active, symptomatic infection caused by respiratory viruses, including COVID-19, influenza viruses, etc.
- Have psoriasis or lichen planus.
- Have Wright's disease/keratosis or hemorrhagic keratosis, or reactive arthritis.
- Have chlorine acne, large common warts, or keratodermatitis.
- Has diabetic foot.
- Have periodontal disease, oral infection, or loose teeth.
- History of malignant tumor within 5 years prior to screening.
- Screening people with a history of liver disease or currently receiving treatment for liver disease, including but not limited to acute or chronic hepatitis, cirrhosis, or liver failure.
- Researchers consider any other unstable clinical disease.
- Oral or inhaled antibiotics were received 4 weeks prior to first administration.
- Immunosuppressants were administered 4 weeks before the first dose.
- Received drugs within 4 weeks prior to screening that may cause hyperkeratosis of the skin.
- Received live attenuated vaccine within 30 days prior to initial administration.
- Participated in clinical trials of any medical device within 3 months prior to screening.
- Active hepatitis B virus infection, active hepatitis C virus infection, or known HIV infection or known syphilis infection.
- Drug abusers.
- Current smoker or former smoker for less than 3 months.
- Suspected allergy to the investigational product or any component of the investigational product, or severe allergy to any drug, food, toxin or other exposure.
- Pregnant or lactating women.
- The people were unable to complete the questionnaires due to their limited educational level, or neither the people themselves nor their families could fill in the subject log card.
- The researchers determined that there were other circumstances that were not suitable for participation in this study.
The study team makes the final eligibility decision.
Where it's taking place
- Guangzhou, Guangdong, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 75 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Guangzhou, Guangdong, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.